NL300130I1 - Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus. - Google Patents

Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus.

Info

Publication number: NL300130I1
Authority: NL; Netherlands
Prior art keywords: recombinant pox; pox virus; expressing; dna; recombinant
Prior art date: 1987-08-28

Application number

NL300130C

Other languages

Dutch (nl)

Other versions

NL300130I2 (en

Original Assignee

Health Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-28

Filing date

2003-07-09

Publication date

2003-09-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300130(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-09 Application filed by Health Research Inc filed Critical Health Research Inc

2003-09-01 Publication of NL300130I1 publication Critical patent/NL300130I1/en

2005-11-01 Publication of NL300130I2 publication Critical patent/NL300130I2/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NL300130C 1987-08-28 2003-07-09 Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus. NL300130I2 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US9071187A	1987-08-28	1987-08-28
US11033587A	1987-10-20	1987-10-20
US18605488A	1988-04-25	1988-04-25
US23439088A	1988-08-23	1988-08-23

Publications (2)

Publication Number	Publication Date
NL300130I1 true NL300130I1 (en)	2003-09-01
NL300130I2 NL300130I2 (en)	2005-11-01

Family

ID=27492413

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NL8820679A NL195051C (en)	1987-08-28	1988-08-24	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus.
NL300130C NL300130I2 (en)	1987-08-28	2003-07-09	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NL300139C NL300139I1 (en)	1987-08-28	2003-11-25	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NL300138C NL300138I2 (en)	1987-08-28	2003-11-25	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NL8820679A NL195051C (en)	1987-08-28	1988-08-24	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NL300139C NL300139I1 (en)	1987-08-28	2003-11-25	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NL300138C NL300138I2 (en)	1987-08-28	2003-11-25	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.

Country Status (17)

Country	Link
JP (3)	JP3348156B2 (en)
KR (1)	KR970011149B1 (en)
AR (1)	AR241939A1 (en)
AT (1)	AT408549B (en)
AU (2)	AU2427588A (en)
BE (1)	BE1002134A5 (en)
CH (2)	CH679934A5 (en)
DE (4)	DE10399032I1 (en)
DK (1)	DK175904B1 (en)
FR (1)	FR2621487B1 (en)
GB (1)	GB2217718B (en)
IL (1)	IL87581A0 (en)
IT (1)	IT1229484B (en)
LU (2)	LU90951I2 (en)
NL (4)	NL195051C (en)
NZ (1)	NZ225970A (en)
WO (1)	WO1989003429A1 (en)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) *	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US7045313B1 (en)	1982-11-30	2006-05-16	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399032I1 (en) *	1987-08-28	2004-01-29	Health Research Inc	Recombinant viruses.
US5286639A (en) *	1987-09-16	1994-02-15	Nippon Zeon Co., Ltd.	Recombinant avipoxvirus
DE3813093A1 (en) *	1988-04-19	1989-11-09	Immuno Ag	RECOMBINANT PLASMIDE, METHOD FOR PRODUCING A RECOMBINANT AVIPOX VIRUS, RECOMBINANT AVIPOX VIRUS, AND USE THEREOF
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
DE68912441T2 (en) *	1988-06-24	1994-05-11	British Tech Group	Nonessential chickenpox virus regions.
US5093258A (en) *	1988-08-26	1992-03-03	Therion Biologics Corporation	Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) *	1988-10-21	1990-04-21	Matthew M. Binns	Fowlpox virus promoter
US6248333B1 (en)	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) *	1990-02-14	1993-04-20	Health Research Incorporated	Recombinant poxvirus internal cores
US5514375A (en) *	1990-08-15	1996-05-07	Virogenetics Corporation	Flavivirus recombinant poxvirus vaccine
MY109299A (en) *	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
FR2668064B1 (en) *	1990-10-23	1994-12-16	Transgene Sa	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT TUMOR.
US5756102A (en) *	1990-11-20	1998-05-26	Virogenetics Corporation	Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5759841A (en) *	1990-11-20	1998-06-02	Virogenetics Corporation	Immunological composition of measles virus utilizing recombinant poxvirus
US6309647B1 (en)	1999-07-15	2001-10-30	Aventis Pasteur	Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5503834A (en) *	1990-11-20	1996-04-02	Virogenetics Corporation	Measles virus recombinant poxvirus vaccine
IE68404B1 (en) *	1990-11-20	1996-06-12	Virogenetics Corp	Measles virus recombinant poxvirus vaccine
US5338679A (en) *	1991-01-08	1994-08-16	Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada	Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5766598A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
DE69233158T2 (en) *	1991-03-07	2004-05-13	Connaught Technology Corp., Greenville	GENETICALLY MANUFACTURED STRAIN FOR VACCINES
US5766597A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Malaria recombinant poxviruses
US5863542A (en) *	1991-03-07	1999-01-26	Virogenetics Corporation	Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5756101A (en) *	1991-07-01	1998-05-26	Pasteur Merieux Serums Et Vaccins	Malaria recombinant poxvirus
AU674491B2 (en) *	1991-03-20	1997-01-02	Virogenetics Corporation	Recombinant poxvirus malaria vaccine
JP3504659B2 (en) *	1991-06-14	2004-03-08	ヴァイロジェネティクスコーポレイション	Immunodeficiency virus recombinant poxvirus vaccine
EP0597016A4 (en) *	1991-07-26	1996-04-24	Virogenetics Corp	Infectious bursal disease virus recombinant poxvirus vaccine.
DK0538496T3 (en) *	1991-08-26	2004-02-23	Baxter Healthcare Sa	Recombinant poultry pox virus with intact FPV tk gene
US5443831A (en) *	1991-10-29	1995-08-22	University Of Delaware	Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6251403B1 (en)	1992-01-13	2001-06-26	Syntro Corporation	Recombinant swinepox virus
US6328975B1 (en)	1992-01-13	2001-12-11	Syntro Corporation	Recombinant swinepox virus
US5869312A (en) *	1992-01-13	1999-02-09	Syntro Corporation	Recombinant swinepox virus
PT623172E (en) *	1992-01-13	2005-02-28	Virogenetics Corp	RECOMBINANT VACCINIA VIRUS FROM MAREK'S DISEASE VIRUS
US6127163A (en) *	1992-01-13	2000-10-03	Syntro Corporation	Recombinant swinepox virus
US6497882B1 (en)	1992-01-13	2002-12-24	Syntro Corporation	Recombinant swinepox virus
US6033904A (en) *	1992-01-13	2000-03-07	Syntro Corporation	Recombinant swinepox virus
JPH08501452A (en) *	1992-09-21	1996-02-20	ビアジーン，インコーポレイティド	Recombinant retrovirus vector for FELV and / or FIV
US5925358A (en) *	1993-02-26	1999-07-20	Syntro Corporation	Recombinant fowlpox viruses and uses thereof
WO1994019014A1 (en) *	1993-02-26	1994-09-01	Syntro Corporation	Recombinant fowlpox virus s-fpv-043 and uses thereof
AU727278B2 (en) *	1993-02-26	2000-12-07	Syntro Corporation	Recombinant fowlpox viruses and uses thereof II
US6136318A (en) *	1993-02-26	2000-10-24	Cochran; Mark D.	Recombinant fowlpox viruses and uses thereof
US5496731A (en) *	1993-03-25	1996-03-05	Xu; Hong-Ji	Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en)	1995-07-10	1997-01-15	Immuno Ag	Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) *	1995-12-01	1999-01-12	Virogenetics Corporation	Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
WO1998004727A1 (en)	1996-07-25	1998-02-05	Therion Biologics Corporation	Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) *	1997-05-07	2000-08-22	University Of Florida	Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) *	1997-08-05	1999-02-18	University Of Florida	Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) *	1997-10-08	2001-06-19	Imran Khan	Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (en)	1997-12-01	1999-06-22	Lintec Corp	Cover tape for carrying chip body and sealing structure
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6602705B1 (en)	1998-12-31	2003-08-05	Chiron Corporation	Expression of HIV polypeptides and production of virus-like particles
WO2001000663A2 (en)	1999-06-28	2001-01-04	Oklahoma Medical Research Foundation	Catalytically active recombinant memapsin and methods of use thereof
WO2001062778A2 (en)	2000-02-23	2001-08-30	Smithkline Beecham Biologicals S.A.	Tumour-specific animal proteins
AR029540A1 (en)	2000-06-28	2003-07-02	Corixa Corp	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND THERAPY OF CA NCER DE PULMoN
WO2002080982A2 (en)	2001-01-12	2002-10-17	Chiron Corporation	Nucleic acid mucosal immunization
ES2258628T3 (en) *	2001-03-08	2006-09-01	Akzo Nobel N.V.	LEPORIPOX-BASED VECTOR VACCINES.
JP4499311B2 (en) *	2001-04-27	2010-07-07	シャープ株式会社	Broadcast receiving terminal
WO2002089747A2 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003004657A1 (en)	2001-07-05	2003-01-16	Chiron Corporation	Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US7211659B2 (en)	2001-07-05	2007-05-01	Chiron Corporation	Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
CA2860702C (en)	2001-12-17	2019-02-26	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
HUE026376T2 (en)	2003-01-06	2016-05-30	Corixa Corp	Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1628680B1 (en)	2003-05-15	2012-10-24	Novartis Vaccines and Diagnostics, Inc.	Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
JP2008513406A (en)	2004-09-22	2008-05-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	Immunogenic composition
EP2360175B1 (en)	2005-11-22	2014-07-16	Novartis Vaccines and Diagnostics, Inc.	Norovirus and Sapovirus virus-like particles (VLPs)
AU2007239095B2 (en)	2006-01-09	2012-05-03	The Regents Of The University Of California	Immunostimulatory combinations for vaccine adjuvants
US7842299B2 (en)	2006-03-14	2010-11-30	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
EP2125868B1 (en)	2007-02-28	2015-06-10	The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
ES2662030T3 (en)	2007-10-15	2018-04-05	Admedus Vaccines Pty Limited	Construction system and uses for it
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
BRPI1005670A8 (en)	2009-01-05	2017-12-26	Epitogenesis Inc	adjuvant compositions and processes of use.
US8664183B2 (en)	2009-02-27	2014-03-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	SPANX-B polypeptides and their use
US8961989B2 (en)	2009-11-20	2015-02-24	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
US20130052221A1 (en)	2010-02-26	2013-02-28	The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services	Dna-protein vaccination protocols
US9795658B2 (en)	2010-04-20	2017-10-24	Admedus Vaccines Pty Ltd	Expression system for modulating an immune response
WO2012106281A2 (en)	2011-01-31	2012-08-09	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
WO2012151272A2 (en)	2011-05-02	2012-11-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
CN103608030A (en)	2011-06-21	2014-02-26	昂科发克特公司	Compositions and methods for therapy and diagnosis of cancer
WO2012178118A1 (en)	2011-06-24	2012-12-27	Epitogenesis Inc.	Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US20150004144A1 (en)	2011-12-02	2015-01-01	The General Hospital Corporation	Differentiation into brown adipocytes
EP2890720B1 (en)	2012-08-30	2019-07-17	The General Hospital Corporation	Compositions and methods for treating cancer
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
EP2895191B1 (en)	2012-09-14	2019-06-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
SG11201508297YA (en)	2013-04-17	2015-11-27	Genzyme Corp	Compositions and methods for treating and preventing macular degeneration
AU2014268603B2 (en)	2013-05-21	2018-03-22	President And Fellows Of Harvard College	Engineered heme-binding compositions and uses thereof
CA2930693A1 (en)	2013-11-15	2015-05-21	The Board Of Trustees Of The Leland Stanford Junior Unversity	Methods of treating heart failure with agonists of hypocretin receptor 2
BR112016017817A2 (en)	2014-02-06	2017-10-10	Genzyme Corp	compositions and methods for the treatment and prevention of macular degeneration
WO2016044707A1 (en)	2014-09-18	2016-03-24	Cedars-Sinai Medical Center	Compositions and methods for treating fibrosis
US20180071380A1 (en)	2015-03-20	2018-03-15	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
WO2016168601A1 (en)	2015-04-17	2016-10-20	Khalid Shah	Agents, systems and methods for treating cancer
EP3285795B1 (en)	2015-04-22	2022-11-16	Cedars-Sinai Medical Center	Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
ES2959642T3 (en)	2015-05-13	2024-02-27	The Us Secretary Of The Department Of Health And Human Services	METHODS AND COMPOSITIONS TO INDUCE AN IMMUNE RESPONSE THROUGH CONSTRUCTIONS WITH CONSERVED ELEMENTS
WO2016196366A1 (en)	2015-05-29	2016-12-08	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en)	2015-06-29	2020-12-23	The Board of Trustees of the Leland Stanford Junior University	Degron fusion constructs and methods for controlling protein production
AU2016367712B2 (en)	2015-12-09	2021-10-07	Jingang Medicine (Australia) Pty Ltd	Immunomodulating composition for treatment
US11285191B2 (en)	2016-07-26	2022-03-29	The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Immunostimulatory compositions and uses therefor
US10917454B1 (en)	2019-08-01	2021-02-09	Rohde & Schwarz Gmbh & Co. Kg	System and method for ATC voice quality assurance
WO2023070072A1 (en)	2021-10-21	2023-04-27	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Retroelement-generated transcription factor decoys
WO2023077147A2 (en)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	T-cell vaccines for patients with reduced humoral immunity
EP4426832A1 (en)	2021-11-03	2024-09-11	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Precise genome editing using retrons
WO2023141602A2 (en)	2022-01-21	2023-07-27	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
WO2023183627A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
EP4499822A1 (en)	2022-03-25	2025-02-05	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Rt-dna fidelity and retron genome editing
WO2023183588A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Methods of assessing engineered retron activity, and uses thereof
AU2023311964A1 (en)	2022-07-18	2025-01-30	Renagade Therapeutics Management Inc.	Gene editing components, systems, and methods of use
WO2024044673A1 (en)	2022-08-24	2024-02-29	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en)	2022-08-25	2024-02-29	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
WO2024233791A1 (en)	2023-05-11	2024-11-14	Seelos Therapeutics, Inc.	Methods of treating neurodegenerative disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK489481A (en) *	1980-11-10	1982-05-11	Searle & Co	PLASMID VECTOR AND METHOD OF PRODUCING THEREOF
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
AU570940B2 (en) *	1982-11-30	1988-03-31	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Process for producing poxvirus recombinants for expression offoreign genes
FR2563434B1 (en) *	1984-04-25	1986-07-25	Transgene Sa	Rabies vaccine and process for its preparation
WO1986000528A1 (en) *	1984-07-05	1986-01-30	Genex Corporation	Cloned gene and method for making and using the same
DD235669A1 (en) *	1985-03-26	1986-05-14	Akad Wissenschaften Ddr	METHOD FOR PRODUCING A BLV-CODED HUEL PROTEIN
WO1986005806A1 (en) *	1985-03-29	1986-10-09	National Research Development Corporation	Infectious bronchitis virus spike protein
EP0213894A3 (en) *	1985-08-23	1987-10-21	Advanced Genetics Research Institute	Defective viral particle vaccines and methods for their use
AU607399B2 (en) *	1985-09-09	1991-03-07	Cetus Corporation	Infectious recombinant virus vaccine for feline leukemia
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU602875B2 (en) *	1985-12-18	1990-11-01	British Technology Group Limited	Newcastle disease virus gene clones
WO1988002022A1 (en) *	1986-09-22	1988-03-24	Commonwealth Scientific And Industrial Research Or	Recombinant poxviruses
AU8075787A (en) *	1986-09-22	1988-04-07	Australian National University, The	Recombinant poxviruses
EP0261940A3 (en) *	1986-09-23	1989-07-05	Applied Biotechnology, Inc.	Pseudorabies vaccines and dna vectors for recombination with pox viruses
EP0284416B1 (en) *	1987-03-27	1995-02-22	Nippon Zeon Co., Ltd.	Recombinant avipoxyvirus
DE10399032I1 (en) *	1987-08-28	2004-01-29	Health Research Inc	Recombinant viruses.
GB8724885D0 (en) *	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
FR2632863B2 (en) *	1987-10-29	1990-08-31	Transgene Sa	RECOMBINANT FOWLPOX VIRUS AND VACCINES DERIVED FROM SUCH VIRUSES
DE68912441T2 (en) *	1988-06-24	1994-05-11	British Tech Group	Nonessential chickenpox virus regions.
DE4090351T1 (en) *	1989-03-08	1997-07-24	Health Research Inc	Recombinant smallpox virus host selection system
EP0953648A3 (en) *	1990-09-25	2007-09-12	Cantab Pharmaceuticals Research Limited	Viral defective vaccine produced by transcomplementing cell line

1987
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/en active Pending
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/en active Pending
1988
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en active Application Filing
- 1988-08-24 JP JP50771588A patent/JP3348156B2/en not_active Expired - Lifetime
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 AT AT0900788A patent/AT408549B/en not_active IP Right Cessation
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/en not_active IP Right Cessation
- 1988-08-24 DE DE3890874A patent/DE3890874C5/en not_active Expired - Lifetime
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 NL NL8820679A patent/NL195051C/en not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/en active Pending
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-28 IL IL87581A patent/IL87581A0/en not_active IP Right Cessation
- 1988-08-29 FR FR888811334A patent/FR2621487B1/en not_active Expired - Lifetime
- 1988-08-29 AR AR88311787A patent/AR241939A1/en active
- 1988-08-29 NZ NZ225970A patent/NZ225970A/en unknown
- 1988-08-29 BE BE8800978A patent/BE1002134A5/en not_active IP Right Cessation
- 1988-08-29 IT IT8821772A patent/IT1229484B/en active
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/en active Protection Beyond IP Right Term
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/en active Pending
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/en not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/en unknown
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/en unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/en unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/en unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/en unknown

Also Published As

Publication number	Publication date
JP3826055B2 (en)	2006-09-27
AU2427588A (en)	1989-05-02
IL87581A0 (en)	1989-01-31
GB2217718A (en)	1989-11-01
CH679934A5 (en)	1992-05-15
DK203689D0 (en)	1989-04-27
GB2217718B (en)	1992-05-20
WO1989003429A1 (en)	1989-04-20
JP2002186494A (en)	2002-07-02
NL300139I1 (en)	2004-02-02
AT408549B (en)	2001-12-27
NZ225970A (en)	1991-01-29
DK203689A (en)	1989-06-27
AR241939A1 (en)	1993-01-29
KR890701757A (en)	1989-12-21
LU90951I2 (en)	2003-01-15
BE1002134A5 (en)	1990-07-24
DE10399031I1 (en)	2004-01-29
IT1229484B (en)	1991-09-03
DE3890874C2 (en)	2003-03-13
AU690210B2 (en)	1998-04-23
NL300138I1 (en)	2004-02-02
KR970011149B1 (en)	1997-07-07
JP2002348255A (en)	2002-12-04
GB8908921D0 (en)	1989-08-02
AU1628895A (en)	1995-08-17
JPH02500879A (en)	1990-03-29
NL300130I2 (en)	2005-11-01
IT8821772A0 (en)	1988-08-29
ATA900788A (en)	1995-05-15
NL300138I2 (en)	2004-03-01
LU91039I2 (en)	2003-11-05
DE3890874C5 (en)	2005-10-20
JP3348156B2 (en)	2002-11-20
CH679933A5 (en)	1992-05-15
DE10399032I1 (en)	2004-01-29
DK175904B1 (en)	2005-06-06
NL8820679A (en)	1989-07-03
FR2621487A1 (en)	1989-04-14
NL195051C (en)	2003-07-01
DE10299049I1 (en)	2004-07-01
FR2621487B1 (en)	1991-10-18

Publication	Publication Date	Title
NL300130I1 (en)	2003-09-01	Recombinant pox viruses, immunological compositions comprising a recombinant pox virus, and method for expressing the DNA in a recombinant pox virus.
NO881064L (en)	1988-09-12	PROCEDURE FOR DETERMINING NUCLEIC ACIDS BY HYBRIDIZATION TECHNIQUE, REAGENT COMBINATION AND TEST PACKAGE FOR CARRYING OUT THE PROCEDURE.
NL192275B (en)	1996-12-02	Protein from the AIDS virus.
NL193884B (en)	2000-09-01	Vibration type transducer and method for its manufacture.
NL193945B (en)	2000-11-01	Process for preparing 4-amino-1-hydroxy-butane-1,1-diphosphonic acid and 6-amino-1-hydroxy-hexane-1,1-diphosphonic acid.
FI942387L (en)	1995-11-25	Method for preparing pharmaceutical compositions, wherein the compositions are based on microemulsion gels and novel gels based on microemulsions
DE3764980D1 (en)	1990-10-25	SYSTEM FOR APPLICATING MEDICINES THROUGH THE SKIN.
NL184939C (en)	1989-12-18	METHOD FOR MANUFACTURING AN INTEGRATED ELECTRICALLY HEATABLE CASTING CAN AND INTEGRATED ELECTRICALLY HEATING CASTING BUS
NO891818D0 (en)	1989-05-02	T4 RECEPTOR PROTEIN, RELATED DNA SEQUENCES AND PREPARATION thereof.
NL7905375A (en)	1980-01-15	PROSTANOIDS, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL PREPARATIONS BASED ON THAT
EP0179139A4 (en)	1987-11-25	Leukemia-associated virus immunogen, vaccine and assay.
NO871025D0 (en)	1987-03-12	POLYPEPTID, DNA AND PROCEDURE FOR PREPARING THEREOF.
DE3785702D1 (en)	1993-06-09	METHOD FOR HANDLING LOADS AND MEANS FOR CARRYING OUT THE SAME.
NO882203L (en)	1988-11-23	DEVICE FOR LABOR CHAIR OR LIKE.
NL7904787A (en)	1979-12-28	METHOD AND SYSTEM FOR FORMING A WIRE BLADE, AND A WIRE BLADE FORMED THEREOF.
DE3888308D1 (en)	1994-04-14	Heat-resistant, sintered aluminum alloy and process for its production.
DE3872189D1 (en)	1992-07-23	HANDLING VEHICLE FOR THE MANIPULATION OF HEAVY, BULKY LOADS.
DE60026666D1 (en)	2006-05-11	Induction of antigen-specific T cells by interferon
ZA984100B (en)	1999-11-15	Process for the detection of HIV antibodies and antigens used in it.
ES1018059Y (en)	1992-07-16	RECOVERABLE FORMWORK FOR JACENAS, FLOOR AND SIMILAR FORGING.
IT8422612A0 (en)	1984-09-11	SPRINGING SUPPORT JAW, PARTICULARLY FOR BUS FINISHES AND SIMILAR.
DE3678707D1 (en)	1991-05-16	A-AMINOARYLDIHYDROPYRIDINLACTONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS.
NL192385B (en)	1997-03-03	6-alkyl-4-phenyl-1,4-dihydro-3,5-pyridinecarboxylic acid esters, process for the preparation thereof and pharmaceutical preparations containing these esters.
IT8804806A0 (en)	1988-02-09	BUCKET BUCKET ASSEMBLY FOR HANDLING MATERIALS, PARTICULARLY SNOW.
ES1018060Y (en)	1993-09-16	RECOVERABLE FORMWORK FOR JACENAS, FLOOR AND SIMILAR FORGING.